Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kids with joint pain: risankizumab trial launches

NCT ID NCT06100744

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 5 times

Summary

This study tests a drug called risankizumab in children with juvenile psoriatic arthritis, a condition causing joint pain and swelling. About 40 kids will receive either risankizumab or the standard drug adalimumab for 24 weeks, with responders continuing for up to 2 years. The goal is to see if risankizumab safely improves symptoms and reduces disease activity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

5 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of juvenile psoriatic arthritis (jPsA) according to International League of Associations for Rheumatology criteria for at least 3 months prior to screening. * Active Disease in \>= 3 joints at screening and at Baseline (swelling not due to deformity, or limitation of motion with pain, tenderness, or both) are eligible for inclusion in the study. * Have had an inadequate response (lack of efficacy after minimum 2-month duration of therapy at maximally tolerated dose), or intolerance to previous or current treatment with at least 1 of the following conventional synthetic disease-modifying antirheumatic drug (csDMARDs): methotrexate (MTX), sulfasalazine, leflunomide, or hydroxychloroquine. Exclusion Criteria: * Have any other autoimmune disease, rheumatic disease (including systemic Juvenile idiopathic arthritis \[JIA\], rheumatoid factor-positive or rheumatoid factor-negative polyarticular JIA, extended oligoarticular JIA, persistent oligoarticular JIA, enthesitis-related arthritis, and undifferentiated JIA), or overlap syndrome. * Prior inadequate response to treatments in the anti-TNF or IL-23 inhibitor classes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Juvenile psoriatic arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

juvenile idiopathic arthritis psoriasis-related juvenile idiopathic arthritis psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Juvenile psoriatic arthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    34 sites in 9 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AP-HP - Hopital Bicetre /ID# 258728

    RECRUITING

    Le Kremlin-Bicêtre, Paris, 94270, France

  • ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO /ID# 276753

    RECRUITING

    Milan, Milano, 20122, Italy

  • Alberta Children's Hospital /ID# 257880

    RECRUITING

    Calgary, Alberta, T3B 6A8, Canada

  • Alder Hey Children's NHS Foundation Trust /ID# 262770

    RECRUITING

    Liverpool, L12 2AP, United Kingdom

  • All X Ray Diagnostic Services Corp /ID# 278523

    RECRUITING

    Miami, Florida, 33126, United States

  • Arkansas Children's Hospital /ID# 258776

    RECRUITING

    Little Rock, Arkansas, 72202, United States

  • Asklepios Klinik Sankt Augustin /ID# 259106

    RECRUITING

    Sankt Augustin, North Rhine-Westphalia, 53757, Germany

  • Azienda Ospedaliero Universitaria Meyer /ID# 258587

    RECRUITING

    Florence, Firenze, 50139, Italy

  • Boston Childrens Health Physicians /ID# 258061

    RECRUITING

    Valhalla, New York, 10595, United States

  • British Columbia Children and Women's Hospital and Health Centre /ID# 257884

    RECRUITING

    Vancouver, British Columbia, V6H 3N1, Canada

  • Centrum Zdrowia Dziecka i Rodziny im Jana Pawla II w Sosnowcu /ID# 277058

    RECRUITING

    Sosnowiec, Silesian Voivodeship, 41-200, Poland

  • Child Neurology Consultants of Austin /ID# 260562

    RECRUITING

    Austin, Texas, 78757-7571, United States

  • Childrens National Medical Center /ID# 259284

    RECRUITING

    Washington D.C., District of Columbia, 20010-2916, United States

  • Chu Bordeaux - Hopital Pellegrin /ID# 258729

    RECRUITING

    Bordeaux, New Aquitaine, 33076, France

  • Cleveland Clinic - Cleveland /ID# 276655

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Columbia University Medical Center /ID# 262587

    RECRUITING

    New York, New York, 10032-3729, United States

  • Hamburger Zentrum fuer Kinder- und Jugendrheumatologie /ID# 259104

    RECRUITING

    Hamburg, 22081, Germany

  • Helios Klinikum Berlin - Buch /ID# 268803

    RECRUITING

    Berlin, 13125, Germany

  • Hospital Sant Joan de Deu /ID# 257568

    RECRUITING

    Esplugues de Llobregat, Barcelona, 08950, Spain

  • Hospital Universitario y Politecnico La Fe /ID# 257567

    RECRUITING

    Valencia, 46026, Spain

  • Hospital for Sick Children /ID# 257879

    RECRUITING

    Toronto, Ontario, M5G 1X8, Canada

  • Indiana University Health Riley Hospital for Children /ID# 259067

    RECRUITING

    Indianapolis, Indiana, 46202, United States

  • Joe Dimaggio Children's Hospital Hollywood /ID# 260634

    RECRUITING

    Hollywood, Florida, 33021, United States

  • M Health Fairview University of Minnesota Medical Center - West Bank /ID# 260111

    RECRUITING

    Minneapolis, Minnesota, 55454, United States

  • Malopolskie Badania Kliniczne /ID# 258777

    RECRUITING

    Cracow, Lesser Poland Voivodeship, 30-002, Poland

  • MetroHealth Medical Center /ID# 262377

    RECRUITING

    Cleveland, Ohio, 44109, United States

  • Monash Health - Monash Medical Centre - Clayton /ID# 260255

    RECRUITING

    Clayton, Victoria, 3168, Australia

  • Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. prof. dr hab. med. /ID# 277050

    RECRUITING

    Warsaw, Masovian Voivodeship, 02-637, Poland

  • Ospedale Pediatrico Bambino Gesu /ID# 258869

    RECRUITING

    Rome, Roma, 00165, Italy

  • SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi /ID# 258785

    RECRUITING

    Lodz, Łódź Voivodeship, 91-738, Poland

  • Sheffield Children's Hospital NHS Foundation Trust /ID# 258848

    RECRUITING

    Sheffield, England, S10 2TH, United Kingdom

  • University Hospitals Bristol and Weston NHS Foundation Trust /ID# 258847

    RECRUITING

    Bristol, BS2 8BJ, United Kingdom

  • University of North Carolina - Children's Hospital /ID# 259286

    RECRUITING

    Chapel Hill, North Carolina, 27514, United States

  • Uniwersytecki Szpital Dzieciecy w Lublinie /ID# 258781

    RECRUITING

    Lublin, Lublin Voivodeship, 20-093, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.